Bank Of America Corp Poseida Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 94,294 shares of PSTX stock, worth $330,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,294

Previous 184,366 48.85%

Holding current value

$330,971

Previous $588,000 53.23%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.0 - $3.46 $180,144 - $311,649	-90,072 Reduced 48.85%	94,294 $275,000
Q1 2024 May 15, 2024	SELL	$2.76 - $4.13 $146,981 - $219,939	-53,254 Reduced 22.41%	184,366 $588,000
Q4 2023 Feb 14, 2024	SELL	$1.83 - $3.51 $172,762 - $331,365	-94,406 Reduced 28.43%	237,620 $798,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.4 $132,597 - $271,585	79,878 Added 31.68%	332,026 $584,000
Q1 2023 May 12, 2023	BUY	$3.08 - $8.73 $719,032 - $2.04 Million	233,452 Added 1248.67%	252,148 $776,000
Q4 2022 Feb 10, 2023	SELL	$3.33 - $6.38 $25,264 - $48,405	-7,587 Reduced 28.87%	18,696 $99,000
Q3 2022 Nov 14, 2022	BUY	$2.43 - $4.51 $8,466 - $15,712	3,484 Added 15.28%	26,283 $92,000
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $16,736 - $44,750	-8,950 Reduced 28.19%	22,799 $58,000
Q1 2022 May 16, 2022	SELL	$3.22 - $7.04 $5,068 - $11,080	-1,574 Reduced 4.72%	31,749 $143,000
Q4 2021 Feb 08, 2022	BUY	$6.23 - $7.6 $25,468 - $31,068	4,088 Added 13.98%	33,323 $227,000
Q3 2021 Nov 15, 2021	BUY	$7.09 - $10.71 $23,992 - $36,242	3,384 Added 13.09%	29,235 $213,000
Q2 2021 Sep 13, 2021	BUY	$7.96 - $10.07 $205,773 - $260,319	25,851 New	25,851 $259,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.1M

Call Options Held

417K

Put Options Held

42.7K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $301M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Poseida Therapeutics, Inc. Transaction History